 This is Tonya Schwere from the Dana-Farber Cancer Institute, and I would like to give you an overview of the rationale and the schema of the Meteor study in metastatic renal cell carcinoma. First, I would like to say that we do have several FDA approved agents for advanced RCC. None of these agents are curative. The agents that we have target essentially the VESCA, the vascular endothelial growth factor, as well as MTOR. And when patients stop responding to drugs that target the VESCA, such as seraphonib and others, this remains an unmet medical, there remains an unmet medical need and many challenges. There is a rationale to target both VEGF and MET, in fact, in renal cell cancer, and another interesting target in this disease. And this stemmed from the fact that resistance to the agents that target VEGF can be overcome by inhibition of MET, and MET itself seems a valid target in renal cell cancer. One drug in particular target both VEGF and MET. It's an oral drug that is called kabuzentinib, which showed evidence of anti-cancer activity in multiple solid tumor, including breast ovarian, prostate, liver cancers. And it's currently FDA approved for one indication, which is the medullary thyroid cancer. One study was conducted, a small study in renal cell cancer of 25 patients that showed some encouraging clinical activity in patients with metastatic advanced kidney cancer that have already progressed on multiple treatments, such as synitinib, pazapinib, and others, these drug that target the VEGF and the VEGF receptor. The response rate in the study was around 30%. But on that, a larger study is now planned and currently accruing called the Meteor clinical trial. The study will have 200 sites, and it's in several countries. It will be an open label study where patients that have already, their tumor, have grown on the drug that I mentioned, will be able to receive either kabuzentinib, the study drug, the experimental drug, or iverolimus, which is an acceptable second line option, which is an mTOR inhibitor, an oral mTOR inhibitor. This will be a 650 patient study with the primary endpoint measuring progression-free survival like many studies in this context. And we offered mostly to the most common type of kidney cancer, which is a clear-cell kidney cancer. The study will be open in multiple places, North America, Europe, Asia-Pacific, and Latin America. We will also look beside just the efficacy. We will be looking at the duration of response, the safety of the drug, and the most important and some element of quality of life with this drug compared to iverolimus. We will be also collecting blood and tissue in order to try as much as possible find any biomarker that can predict response to kabuzentinib in a better way. There is no limit on the number of additional anti-cancer therapies patients would have received. For more information, the study has a website. The website is www.meteorclinicaltrial.com. Thank you for your attention.